Navigation Links
PipetBoy Pipettor

ProductsPipetBoy Pipettor
Company MIDSCI
Item PipetBoy Pipettor
Features Inquire
Description The PipetBoy Pipettor is light as a feather and ergonomically designed for ease of handling. The aspiration speed can be continuously adjusted. The pipette mount rubber is made of silicone and can be autoclaved. Two dosing knobs enable fine dosing to be carried out when filling and emptying plastic an/or glass pipettes from 0.1 to 100 ml. Each PipetBoy comes complete with: power supply-Independent Pipettor, rechargeable 9V NiCd battery, 0.45l sterile filter, and wall mount. The PipetBoy comes in 5 different colors: Grey, Green, Red, Blue, and Transparent. Click on the link below for all order #s and a list of accessories.
Info MIDSCI
Customer Service: (800) 227-9997
Web site: http://www.midsci.com

Related medicine products :

1. Apricot Personal Pipettor
2. Aquarius 96 Multichannel Pipettor
3. Aquarius 384 Multichannel Pipettor
4. Cartesian Pipettor
5. AlphaForce Pipettor
6. AlphaPette Pipettor - Range 100l - 1000l
7. Corning Lambda Single Channel Pipettor, 100-1000 ul
8. Corning Lambda Single Channel Pipettor, 20-200 ul
9. AlphaPette Pipettor - Range 20l - 200l
10. Corning Lambda Single Channel Pipettor, 2-20 ul
11. AlphaPette Pipettor - Range 2l - 20l
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 1AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 2AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 1Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 2Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 4Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 5